Table 1 Patient characteristics and treatment disposition

From: Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Variable

 

Nivo+CT (n = 22)

Ipi+Nivo+CT (n = 22)

Age—median (range), years

 

69.5 (45.6–79.3)

63.1 (39.4–77.5)

Age—number (%)

<65 years

10 (45)

13 (59)

>65 years

12 (55)

9 (41)

Sex—number (%)

Female

12 (55)

7 (32)

Male

10 (45)

15 (68)

Race—number (%)

Asian NOS

3 (14)

1 (5)

Black

0 (0)

3 (14)

White

19 (86)

18 (82)

Smoking status—number (%)

Never smoker

5 (23)

5 (23)

Former smoker/current smoker

17 (77)

17 (77)

Stage—number (%)

Stage IB (≥4 cm) or II

11 (50)

9 (41)

Stage IIIA

11 (50)

13 (59)

Histology—number (%)

Non-squamous

17 (77)

17 (77)

Squamous

5 (23)

5 (23)

ECOG PS—number (%)

0

10 (45)

16 (73)

1

12 (55)

6 (27)

Mediastinal staging—number (%)

EBUS

21 (95)

22 (100)

Mediastinoscopy

1 (5)

0 (0)

  1. EBUS, endobronchial ultrasound; NOS, not otherwise specified. Non-squamous includes adenocarcinoma, carcinoma with neuroendocrine features, NOS NSCLC, sarcomatoid carcinoma and large cell carcinoma.
Back to article page